

Takeyuki Hiramatsu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1197269/publications.pdf>

Version: 2024-02-01

14
papers

177
citations

1163117

8
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

247
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS). <i>Clinical and Experimental Nephrology</i> , 2020, 24, 526-540.	1.6	33
2	Recent analysis of status and outcomes of peritoneal dialysis in the Tokai area of Japan: the second report of the Tokai peritoneal dialysis registry. <i>Clinical and Experimental Nephrology</i> , 2016, 20, 960-971.	1.6	27
3	Quality of Life and Emotional Distress in Peritoneal Dialysis and Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 366-372.	0.9	23
4	Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2015, 19, 598-605.	0.9	21
5	Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 1266-1280.	1.6	21
6	Liraglutide relieves cardiac dilated function than <sc>DPP</sc>â€4 inhibitors. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13007.	3.4	16
7	A Pilot Study Examining the Effects of Tolvaptan on Residual Renal Function in Peritoneal Dialysis for Diabetics. <i>Peritoneal Dialysis International</i> , 2015, 35, 552-558.	2.3	11
8	Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study. <i>Drug Research</i> , 2017, 67, 640-646.	1.7	9
9	Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS). <i>Clinical and Experimental Nephrology</i> , 2020, 24, 893-909.	1.6	6
10	Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412097122.	2.0	5
11	Icodextrin eliminates phosphate and ameliorates cardiac hypertrophy and valvular calcification in patients with end-stage renal disease and diabetes mellitus undergoing peritoneal dialysis. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2013, 29, 9-13.	0.1	3
12	When should icodextrin be started to improve atherosclerosis in peritoneal dialysis patients?. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2013, 29, 4-8.	0.1	1
13	The Vasopressin 2 Receptor Antagonist Tolvaptan Improves Nutrition and Inflammatory States in Peritoneal Dialysis Patients with Diabetes Mellitus. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2015, 31, 30-3.	0.1	1
14	Higher dental care is positively associated with key prognosis factors in peritoneal dialysis patients: findings from a retrospective study. <i>Renal Replacement Therapy</i> , 2022, 8, .	0.7	0